Jessica Serra | executive |
Mark Foley | executive |
Dustin Sjuts | executive |
Tobin Schilke | executive |
Seamus Fernandez | analyst |
Mikaela Franceschina | analyst |
David Amsellem | analyst |
Stacy Ku | analyst |
Annabel Samimy | analyst |
Uy Ear | analyst |
Serge Belanger | analyst |
Douglas Tsao | analyst |
Terence Flynn | analyst |
Navann Ty Dietschi | analyst |
Welcome to the Revance Therapeutics Third Quarter 2023 Financial Results and Corporate Update Conference Call. [Operator Instructions] As a reminder, this call is being recorded today, Wednesday, November 8, 2023.I would now like to turn the conference call over to Jessica Serra, Head of Investor Relations, Communications and ESG for Revance. Please go ahead.
Thank you, operator.
Joining us on the call today from Revance are Chief Executive Officer, Mark Foley; President, Dustin Sjuts; and Chief Financial Officer, Toby Schilke.During this conference call, management will make forward-looking statements, including statements related to guidance, related to guidance, positive adjusted EBITDA, adjusted gross margin, operating leverage, blockbuster potential.